We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
+$27.8M
Cap. Flow %
6.12%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Miscellaneous 77.68%
2 Healthcare 21.52%
3 Technology 0.35%
4 Consumer Staples 0.21%
5 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
126
Cardiff Oncology
CRDF
$104M
– –
-25,606
Closed -$125K
DBVT
127
CALL
DBV Technologies
DBVT
$739M
– –
-12
Closed -$261K
EDSA icon
128
Edesa Biotech
EDSA
$39.7M
– –
-1,116
Closed -$65K
KYNB
129
CALL
Kyntra Bio
KYNB
$31.5M
– –
-37
Closed -$5.57M
FOLD
130
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-2,350
Closed -$2.84M
FOLD
131
DELISTED
Amicus Therapeutics
FOLD
– –
-155,044
Closed -$1.87M
FOLD
132
PUT
DELISTED
Amicus Therapeutics
FOLD
– –
-1,656
Closed -$2M
EOCN
133
Eocene Ltd. Ordinary Shares
EOCN
$3.88M
– –
-31
Closed -$599K
INSM icon
134
Insmed
INSM
$26.2B
– –
-15,000
Closed -$303K
INSM icon
135
PUT
Insmed
INSM
$26.2B
– –
-412
Closed -$833K
MDGL icon
136
Madrigal Pharmaceuticals
MDGL
$12.1B
– –
-1,500
Closed -$232K
OEF icon
137
CALL
iShares S&P 100 ETF
OEF
$20.1B
– –
-2,115
Closed -$35.6M
SLS icon
138
SELLAS Life Sciences
SLS
$2.28B
– –
-1,566
Closed -$96K
SPY icon
139
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$799B
– –
-4,001
Closed -$116M
TLRY icon
140
PUT
Tilray
TLRY
$549M
– –
-106
Closed -$15.3M
TPST icon
141
Tempest Therapeutics
TPST
$12.5M
– –
-87
Closed -$187K
TTNP
142
DELISTED
Titan Pharmaceuticals
TTNP
– –
-422
Closed -$314K
VKTX icon
143
PUT
Viking Therapeutics
VKTX
$3.49B
– –
-3,873
Closed -$6.75M
XYLO
144
DELISTED
Xylo Technologies
XYLO
– –
-7,418
Closed -$1.01M
KA
145
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,428
Closed -$482K
YTEN
146
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
– –
-50
Closed -$68K
BPTH
147
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-2,427
Closed -$437K
APTX
148
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-41,037
Closed -$1.19M
SIOX
149
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-16,909
Closed -$327K
OPNT
150
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-43,736
Closed -$781K
3 4 5
6
7

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management deployed $27.8M of net new capital in Q4 2018, opening 35 new positions and adding to 35 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.

By sector, the portfolio is most concentrated in Miscellaneous at 78% of assets, down from 84% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $8.71M trimmed.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.